FDAnews
www.fdanews.com/articles/202878-polyganics-enrolls-first-patient-in-clinical-trial-of-dura-sealant-patch

Polyganics Enrolls First Patient in Clinical Trial of Dura Sealant Patch

May 24, 2021

Polyganics has enrolled the first participant in a clinical trial evaluating the safety and efficacy of Liqoseal, a synthetic dura sealant patch for use as an adjunct to standard methods of cranial dural repair.

The device provides watertight closure of the brain’s dura mater and helps to reduce cerebrospinal fluid leakage. It also supports regeneration of the dura mater by serving as a scaffold for new fibrotic-layer formation.

The study will gauge the device’s ability to safely reduce intra- or postoperative cerebrospinal fluid leakage in patients undergoing cranial surgery. It will involve 228 patients across up to 20 sites in the U.S. and Europe.

View today's stories